logo

Cara Therapeutics Inc. (CARA)



Trade CARA now with
  Date
  Headline
9/28/2022 7:15:45 AM Cara Therapeutics Submits NDA In Japan For Approval Of Difelikefalin For Pruritus In Hemodialysis
9/8/2022 8:21:59 AM Cara Therapeutics Presents Late-Breaking Results Of KOMFORT Phase 2 Trial Of Difelikefalin For Pruritus
8/19/2022 1:04:50 AM Vifor Fresenius Medical Care Renal Pharma, Cara Therapeutics Get Approval For Kapruvia From Swissmedic
4/28/2022 1:12:18 AM VFMCRP, Cara Therapeutics Announce European Commission Granted Marketing Authorization To Kapruvia
2/28/2022 1:05:16 AM Vifor :Kapruvia Receives Positive CHMP Opinion For Treatment Of moderate-to-severe Pruritus In Hemodialysis Patients
2/25/2022 7:45:38 AM Cara: Kapruvia Gets Positive CHMP Opinion For Treatment Of Moderate-to-severe Pruritus
12/20/2021 7:18:06 AM Cara Therapeutics: CMS Grants TDAPA To KORSUVA Injection In Anti-pruritic Functional Category
10/4/2021 7:30:15 AM Cara Therapeutics Presents Results Of KARE Phase 2 Trial Of Oral KORSUVA At EADV Congress
8/24/2021 1:04:16 AM Vifor Pharma, Cara Therapeutics: FDA Approves KORSUVA Injection For Moderate-to-severe Pruritus In Hemodialysis Patients